title: Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors.
abstract: Cytomegalovirus (CMV) reinfection of seropositive individuals has been associated with adverse outcomes in organ transplantation and is a frequent cause of congenital infection. Previously we demonstrated that mismatching of CMV glycoprotein H (gH) serotypes was associated with CMV disease after renal transplantation. Because the antigen domain 2 (AD2) epitope of glycoprotein B (gB) is conserved among CMV isolates and is one of the known targets of neutralizing antibodies, in this study we investigated whether antibodies against the epitope contribute to protection from CMV reinfection in renal transplantation, irrespective of gH serological matching. For this purpose, the gB and gH serology and clinical outcomes were analyzed retrospectively for 77 transplant recipients in the donor positive/recipient positive setting, who were managed by preemptive strategy. We found that there was a good negative correlation between the numbers of antigenemia-positive cells and the levels of antibodies against gB AD2 in the CMV-gH antibody matched group, but not in the CMV-gH antibody mismatched group. None of the recipients with antibodies against both gB AD2 and strain-specific epitopes of gH have experienced CMV disease during 6 month after transplantation, while 28% of those who lacked either/both antibody response needed preemptive therapy. Because the outcome was statistically significant, antibodies against gB AD2 can be a useful indicator to predict emergence of CMV disease for preemptive therapy, in addition to antibodies against the mismatched gH types.
authors.affiliation: Department of Microbiology, Fukushima Medical University, Fukushima, Japan. keikun@fmu.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Ishibashi
authors.forename: T
authors.initials: T
authors.lastname: Tokumoto
authors.forename: H
authors.initials: H
authors.lastname: Shirakawa
authors.forename: K
authors.initials: K
authors.lastname: Hashimoto
authors.forename: K
authors.initials: K
authors.lastname: Ikuta
authors.forename: N
authors.initials: N
authors.lastname: Kushida
authors.forename: T
authors.initials: T
authors.lastname: Yanagida
authors.forename: K
authors.initials: K
authors.lastname: Shishido
authors.forename: K
authors.initials: K
authors.lastname: Aikawa
authors.forename: H
authors.initials: H
authors.lastname: Toma
authors.forename: N
authors.initials: N
authors.lastname: Inoue
authors.forename: O
authors.initials: O
authors.lastname: Yamaguchi
authors.forename: K
authors.initials: K
authors.lastname: Tanabe
authors.forename: T
authors.initials: T
authors.lastname: Suzutani
mesh_terms: D000914:Antibodies, Viral / Q000097:blood* / Q000276:immunology; D000956:Antigens, Viral / Q000737:chemistry / Q000276:immunology*; D003587:Cytomegalovirus / Q000145:classification / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000276:immunology* / Q000821:virology; D000939:Epitopes / Q000235:genetics / Q000276:immunology*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology; D012703:Serotyping; D013045:Species Specificity; D014019:Tissue Donors; D014759:Viral Envelope Proteins / Q000737:chemistry / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D000939:Epitopes; D014759:Viral Envelope Proteins; C040495:glycoprotein B, Simplexvirus; C071440:glycoprotein H, Cytomegalovirus